Monoclonal antibodies; randomised controlled trials and real-world studies in asthma

E-poster session
Chairs: P. Berger (Bordeaux, France), C. Pelaia (Catanzaro (CZ), Italy)

Late Breaking Abstract - Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX) P. McDowell (Belfast, United Kingdom), S. Diver (Leicester, United Kingdom), J. Yang (Glasgow, United Kingdom), C. Borg (Oxford, United Kingdom), J. Busby (Belfast, United Kingdom), V. Brown (Belfast, United Kingdom), R. Shrimanker (Oxford, United Kingdom), C. Cox (Belfast, United Kingdom), C. Brightling (Leicester, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom), I. Pavord (Oxford, United Kingdom), L. Heaney (Belfast, United Kingdom)
Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab J. Yang (Glagow, United Kingdom), J. Busby (Belfast, United Kingdom), L. Heaney (Belfast, United Kingdom), C. Brightling (Leicester, United Kingdom), I. Pavord (Oxford, United Kingdom), K. Borg (Oxford, United Kingdom), P. Mcdowell (Belfast, United Kingdom), S. Diver (Leicester, United Kingdom), R. Shrimanker (Oxford, United Kingdom), S. Smith (Glasgow, United Kingdom), M. Shepherd (Glasgow, United Kingdom), W. Lee (Glasgow, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom)
Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma A. Moran (Oxford, United Kingdom), S. Ramakrishnan (Oxford, United Kingdom), C. Borg (Oxford, United Kingdom), C. Connolly (Oxford, United Kingdom), S. Couillard (Oxford, United Kingdom), C. Mwasuku (Oxford, United Kingdom), I. Pavord (Oxford, United Kingdom), T. Hinks (Oxford, United Kingdom), L. Lehtim?ki (Tampere, Finland)
Relationship between baseline fraction of exhaled nitric oxide (FeNO) and response to anti-IL-5/5R therapies in severe eosinophilic asthma (SEA) J. Kavanagh (London, United Kingdom), A. Hearn (London, United Kingdom), C. Roxas (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thomson (London, United Kingdom), V. Payne (London, United Kingdom), G. D'Ancona (London, United Kingdom), B. Kent (Dublin, United Kingdom), J. Dhariwal (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), D. Jackson (London, United Kingdom)
Sputum analysis reveals eosinophilic inflammation in difficult-to-control asthma patients with low blood eosinophils and FENO. L. Keulers (LEEUWARDEN, Netherlands), A. Van Der Meer (LEEUWARDEN, Netherlands), A. Ten Brinke (LEEUWARDEN, Netherlands)
Dual biologic therapy with mepolizumab a novel solution to dupilumab-induced conjunctivitis B. Philipenko (Calgary, Canada), B. Walker (Calgary, Canada), P. Mitchell (Calgary, Canada), M. Ramsahai (Calgary, Canada)
Severe asthma outcomes over 18-months treatment with mepolizumab, and comorbidities in non-responders. L. Elsey (Manchester, United Kingdom), J. Wingfield-Derby (Manchester, United Kingdom), L. Holmes (Manchester, United Kingdom), L. Maguire (Manchester, United Kingdom), K. Newman (Manchester, United Kingdom), T. Pantin (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom)
Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma J. Kavanagh (London, United Kingdom), C. Roxas (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thomson (London, United Kingdom), V. Payne (London, United Kingdom), A. Hearn (London, United Kingdom), B. Kent (London, United Kingdom), G. D'Ancona (London, United Kingdom), J. Dhairwal (London, United Kingdom), A. Nanzer (London, United Kingdom), D. Jackson (London, United Kingdom)
Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. M. Luzietoso (PARIS CEDEX 18, France), M. Ghanem (PARIS CEDEX 18, France), P. Le Guen (PARIS CEDEX 18, France), C. Taillé (PARIS CEDEX 18, France)
Characterising individual response to mepolizumab treatment D. Jackson (London, United Kingdom), R. Price (Stevenage, Hertfordshire, United Kingdom), S. Yancey (Research Triangle Park, NC, United States of America), R. Buhl (Mainz, Germany), S. Wenzel (Pittsburgh, PA, United States of America)
Mepolizumab improves lung function under real-world settings in REALITI-A study F. Schleich (Liege, Belgium), R. Chaudhuri (Glasgow, United Kingdom), G. Canonica (Milan, Italy), X. Munoz Gall (Barcelona, Spain), F. Funke (Essen, Germany), B. Pek (Quebec, QC, Canada), S. Pollard (Louisville, KY, United States of America), A. Maxwell (Stevenage, Hertfordshire, United Kingdom), S. Joksaite (London, United Kingdom), R. Price (Stevenage, Hertfordshire, United Kingdom), R. O'Reilly (Stevenage, Hertfordshire, United Kingdom), M. Van Dyke (Collegeville, PA, United States of America), S. Yang (Collegeville, PA, United States of America), P. Howarth (Brentford, Middlesex, United Kingdom)
Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma J. Kavanagh (London, United Kingdom), C. Roxas (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thomson (London, United Kingdom), V. Payne (London, United Kingdom), A. Hearn (London, United Kingdom), B. Kent (London, United Kingdom), G. D'Ancona (London, United Kingdom), J. Dhariwal (London, United Kingdom), A. Nanzer (London, United Kingdom), D. Jackson (London, United Kingdom)
Serum Amphiregulin expression in severe asthma patients treated with anti-IL-5 therapy D. Bagnasco (GENOVA (GE), Italy), A. Riccio (GENOVA (GE), Italy), L. De Ferrari (GENOVA (GE), Italy), A. Massolo (Pisa, Italy), M. Caminati (Verona, Italy), A. Manfredi (GENOVA, Italy), G. Senna (Verona, Italy), G. Passalacqua (GENOVA, Italy)
Omalizumab is an effective intervention in severe asthma with aspergillus sensitisation. P. Wark (NewcastleNew Lambton Heights (NSW)Newcastle, Australia), S. Hussaini (NNewcastleew Lambton Heights (NSW), Australia), C. Holdar (NewcastleNew Lambton Heights (NSW), Australia), H. Powell (NewcastleNewcastleNew Lambton Heights (NSW), Australia), C. Oldmeadow (NewcastleNewcastleNewcastleNew Lambton Heights (NSW), Australia), P. Gibson (NewcastleNewcastleNewcastleNew Lambton Heights (NSW), Australia)
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis D. Bagnasco (Genoa, Italy), G. Passalacqua (Genoa, Italy)
Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy A. Maglio (Baronissi (SA), Italy), C. Vitale (Baronissi (SA), Italy), S. Pellegrino (Baronissi (SA), Italy), C. Calabrese (Naples, Italy), R. Parente (Baronissi (SA), Italy), M. Triggiani (Baronissi (SA), Italy), C. Stellato (Baronissi (SA), Italy), C. Pelaia (Catanzaro, Italy), G. Pelaia (Catanzaro, Italy), A. Vatrella (Baronissi (SA), Italy)
Are serum immunoglobulins a predictive biomarker of response for anti-IL5 therapies? S. LAURET (Toulouse, France), L. Guilleminault (Toulouse, France), E. Noel-Savina (Toulouse, France), G. Prevot (Toulouse, France), D. Brouquieres (Toulouse, France), A. Didier (Toulouse, France)
The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment H. Joplin (Liverpool (Merseyside), United Kingdom), D. Mclenaghan (Liverpool (Merseyside), United Kingdom), L. Jones (Liverpool (Merseyside), United Kingdom), R. Robinson (Liverpool (Merseyside), United Kingdom), K. Hunter (Liverpool (Merseyside), United Kingdom), C. Lowe (Liverpool (Merseyside), United Kingdom), V. Flynn (Liverpool (Merseyside), United Kingdom), L. Root (Liverpool (Merseyside), United Kingdom), H. Burhan (Liverpool (Merseyside), United Kingdom)
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements N. Hanania (Houston, United States of America), J. Maspero (Buenos Aires, Argentina), R. Panettieri (New Brunswick, United States of America), M. Castro (Kansas City, United States of America), N. Daizadeh (Cambridge, United States of America), M. Djandji (Cambridge, United States of America), B. Ortiz (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), Y. Deniz (Tarrytown, United States of America)
Efficacy of tezepelumab in patients with low and high bronchodilator reversibility in PATHWAY J. Corren (Los Angeles, CA, United States of America), M. Liu (Baltimore, MD, United States of America), K. Bowen (Gaithersburg, MD, United States of America), K. Salapa (Warsaw, Poland), G. Colice (Gaithersburg, MD, United States of America), J. Llanos-Ackert (Thousand Oaks, CA, United States of America)